Shares of JanOne Inc. (JAN) were up 7.0% at $8.25 at last check in pre-market trading. During the last trading session, JanOne stock closed at $7.71, an increase of 5.76 percent or $0.42. JanOne stock fluctuated between $7.30 and $7.81 during the session. Within the past 12 months, JanOne stock has advanced 95.69%, and in the last week, it has advanced 10.62%.
The JanOne stock lost -17.98% in the last six months, while it gained 15.77% in the last three months. Thus far this year, JanOne stock has returned 57.67%. The stock of JanOne is rising when no news is available, so there may be some reason to believe that recent developments will provide additional information about the stock.
How has JanOne been recently?
JanOne focuses on treating diseases that cause intense pain. It is JanOne’s goal to treat disease-related pain by reducing the need for opioid prescriptions that can lead to opioid abuse through the reduction of pain at its source. In addition, JanOne is researching nonaddictive pain medication solutions. The company’s lead candidate, JAN101, pertains to the treatment of peripheral artery disease (“PAD”), a condition that affects more than 8.5 million Americans. Specifically, JanOne provides funding for PAD research, technology implementation, and education.
In recent news, JanOne announced it has selected CPC Clinical Research (CPC), a full-service academic research organization (ARO), to manage the Phase 2b clinical trial of lead product candidate JAN101 for periphery arterial disease (PAD).
- The CPC will utilize its expertise in planning, executing, and managing JanOne’s study, in collaboration with JanOne’s recently announced regulatory partner Avania.
- JanOne is delighted to have CPC’s team involved in JanOne’s Phase 2b trial after they have an outstanding reputation for clinical trial management.
- As CPC operates with the highest standards of excellence, they ensure the integrity and success of JanOne study.
How will JanOne Stock conduct the trial?
In Janone’s pivotal Phase 2b study for PAD, two doses of JAN101 (40 and 80 mg) will be evaluated in a 6-month, placebo-controlled trial for diabetics with PAD. The plans of JanOne are to study 300 diabetics with PAD in three groups of 100 patients each. As a result of restoring vascular function, the primary endpoint set by JanOne is the ability of patients to walk without pain or fatigue. A secondary endpoint of JanOne is to reduce pain, improve blood flow to the affected muscle and improve quality of life.
